Taken together, our findings establish a novel regulatory circuit of NF-κB activation by ERK8 upon As2O3 treatment, and implicate the potential of As2O3 in targeting lung cancers with high ERK8 expression. The gene discussed is NFKB1; the disease is lung cancer.